Oncolytic Virotherapy: Clinical Trials

13 trials of Oncolytic Virotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 unknown, 3 completed, 2 not yet recruiting, 2 recruiting. 6 Phase 2, 5 Early Phase 1, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 2, Not yet recruiting 2, Recruiting 1, Terminated 1
Early Phase 15Unknown 5
Phase 13Completed 2, Recruiting 1
Phase 31Terminated 1

Follow Oncolytic Virotherapy: new trials by email Literature Review of Oncolytic Virotherapy trials Research Report on Oncolytic Virotherapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
H101, Camrelizumab - Pancreatic Cancer
Phase 2Not yet recruitingFudan University302026-12-012025-08-07
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer
Phase 2Not yet recruitingJun Huang1142026-06-012026-04-28
Clinical Study of Oncolytic Virus in Glioblastoma
oncolytic virus - Glioblastoma (GBM)
Phase 1 / Phase 2RecruitingMianyang Central Hospital202023-11-022025-12-19
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Recombinant oncolytic herpes simplex virus type 1 (R130) - Sarcoma, Carcinoma
Early Phase 1UnknownShanghai Yunying Medical Technology202023-06-242023-07-27
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Recombinant oncolytic herpes simplex virus type 1 (R130) - Lung Cancer, Bronchial Cancer
Early Phase 1UnknownShanghai Yunying Medical Technology242023-03-302023-06-02
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Recombinant oncolytic herpes simplex virus type 1 (R130) - Head and Neck Cancer, Esophageal Cancer
Early Phase 1UnknownShanghai Yunying Medical Technology92023-03-272023-04-26
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
Recombinant oncolytic herpes simplex virus type 1 (R130) - Sarcoma, Carcinoma
Early Phase 1UnknownShanghai Yunying Medical Technology202023-03-022023-05-16
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Re-resection, Temozolomide, Lomustine - Glioblastoma, Glioblastoma Multiforme
RecruitingJasper Gerritsen4642023-01-012024-02-28
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
Recombinant L-IFN adenovirus injection - Head and Neck Cancer, Melanoma
Early Phase 1UnknownShanghai Fengxian District Central Hospital282021-11-302022-02-01
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
ON-01, ONF - Glioblastoma Multiforme, Gliomas, Malignant
Phase 1 / Phase 2CompletedBeijing Neurosurgical Institute382018-08-012024-08-20
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
DNX-2401, pembrolizumab - Brain Cancer, Brain Neoplasm
Phase 2CompletedDNAtrix, Inc.492016-10-062021-07-15
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Single intratumoral injection of DNX-2401, Interferon-gamma - Glioblastoma or Gliosarcoma
Phase 1CompletedDNAtrix, Inc.372014-09-112018-07-16
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
CG0070 Adenovirus Vector, Control Arm: Quadruple Choice - Transitional Cell Carcinoma, Bladder Cancer
Phase 2 / Phase 3TerminatedCG Oncology, Inc.222014-03-012021-04-14

Conditions studied

Glioblastoma (5)  ·  Breast Neoplasms (4)  ·  Head and Neck Neoplasms (4)  ·  Lung Neoplasms (4)  ·  Brain Neoplasms (3)  ·  Glioma (3)  ·  Pancreatic Neoplasms (3)  ·  Sarcoma (3)  ·  Carcinoma (2)  ·  Colorectal Neoplasms (2)  ·  Gliosarcoma (2)  ·  Liver Neoplasms (2)  ·  Melanoma (2)  ·  Neoplasms (2)  ·  Neoplasms, Nerve Tissue (2)

Sponsors

Shanghai Yunying Medical Technology (4)  ·  DNAtrix, Inc. (2)  ·  Beijing Neurosurgical Institute (1)  ·  CG Oncology, Inc. (1)  ·  Fudan University (1)  ·  Jasper Gerritsen (1)  ·  Jun Huang (1)  ·  Mianyang Central Hospital (1)  ·  Shanghai Fengxian District Central Hospital (1)

Countries

China (8)  ·  United States (4)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Switzerland (1)

Top investigators

Alex W Yeung, MBBS (1)  ·  Frederick Lang, MD (1)  ·  Haitao Wu, Phd (1)  ·  Jasper Gerritsen, MD PhD (1)  ·  Jun Huang (1)  ·  Karen Fink, MD, PhD (1)  ·  Nam Tran, MD, PhD (1)  ·  Nancy Gady, BS (1)  ·  Rong Zhang, MD (1)  ·  Vinay Puduvalli, MBBS (1)

Results publications

PMID 32067509, PMID 35399603, PMID 37188783, PMID 38719544